Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial

BACKGROUND: Cardiotoxicity is a major concern following doxorubicin (DOX) use in the treatment of malignancies. We aimed to investigate whether deferoxamine (DFO) can prevent acute cardiotoxicity in children with cancer who were treated with DOX as part of their chemotherapy. RESULTS: Sixty-two newl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahimi, Kosar, Amoozgar, Hamid, Zareifar, Soheila, Shahriari, Mahdi, Zekavat, Omid Reza, Karimi, Mehran, Fathpour, Gholamreza, Saleh, Fazl, Shakibazad, Nader, Bordbar, Shayan, Bordbar, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039151/
https://www.ncbi.nlm.nih.gov/pubmed/36961611
http://dx.doi.org/10.1186/s43044-023-00347-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039151/
https://www.ncbi.nlm.nih.gov/pubmed/36961611
http://dx.doi.org/10.1186/s43044-023-00347-4

Ejemplares similares